A guide to the management of blood pressure in the diabetic hypertensive patient

American Journal of Cardiovascular Drugs

Volumn 9, Issue 3, 2009, Pages 149-162

  Shammas, Nicolas W ^a   Sica, Domenic A ^b   Toth, Peter P ^a,c,d  

^a MIDWEST CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^c Sterling Rock Fails Clinic Ltd   (United States)

^d UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; POTASSIUM SPARING DIURETIC AGENT; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT;

ANGIONEUROTIC EDEMA; BLOOD PRESSURE REGULATION; COMORBIDITY; CONGESTIVE HEART FAILURE; COUGHING; DIABETES MELLITUS; DIABETIC PATIENT; DRUG DOSE TITRATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GLUCOSE INTOLERANCE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY DISEASE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MICROANGIOPATHY; OBESITY; ORTHOSTATIC HYPOTENSION; OXIDATIVE STRESS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYNCOPE; VASCULAR DISEASE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 66849097993     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03256572     Document Type: Review

References (108)

1. Korhonen P, Aarnio P, Saaresranta T, et al. Glucose homeostasis in hypertensive subjects. Hypertension 2008; 51: 945-9
2. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the roleofinsulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-81
3. Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 2005; 25: 391-406
4. Golomb BA, Dimsdale JE, White HL, et al. Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial. Arch Intern Med 2008; 168: 721-7
5. Welborn TA, Breckenridge A,Rubinstein AH, etal. Serum-insulininessential hypertension and in peripheral vascular disease. Lancet 1966; 1: 1136-7
6. Swislocki ALM, Hoffman BB, Reaven GM. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens 1989; 2: 419-23
7. Ferrannini E, Buzzigoli G, Bonadona R. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-7
8. Ferrannini E, Natali A, Capaldo B, et al., for the European Group for the Study of Insulin Resistance (EGIR). Insulin resistance, hyper-insulinemia, and blood pressure: role of age and obesity. Hypertension 1992; 30: 1144-9
9. Lissner L, Bengtsson C, Lapidus L, et al. Fasting insulin in relation to subsequent blood pressure changes and hypertension in women. Hypertension 1992; 20: 797-801
10. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97
11. Haffner SM, Mykkanen L, Festa A, et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the pre-diabetic state. Circulation 2000; 101: 975-80
12. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-4
13. Festa A, D'AgostinoJr R, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-7
14. Trepels T, Zeiher AM, Fichtlscherer S. The endothelium and inflammation. Endothelium 2006; 13: 423-9
15. Dogra G, Irish A, Chan D, et al. Insulin resistance, inflammation, and blood pressure determine vascular dysfunction in CKD. Am J Kidney Dis 2006; 48: 926-34
16. Khosla N, Sarafidis PA, Bakris GL. Microalbuminuria. Clin Lab Med 2006; 26: 635-53
17. Hypertension in Diabetes Study Investigators. Hypertension in Diabetes Study (HDS): II, increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993; 11: 319-25
18. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001; 322 (7277): 15-8
19. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321 (7258): 405-12
20. Laasko M. Benefits of strict glucose and blood pressure control in type 2 diabetes: lessons from the UK Prospective Diabetes Study. Circulation 1999; 99: 461-2
21. Abbott RD, Donahue RP, Kannel WB, et al. The impact of diabetes on survival following myocardial infarction in men versus women: the Framingham Study. JAMA 1988; 260: 3456-60
22. Gilbert RE, Kim C, Kelly DJ, et al. Heart failure and nephropathy: catastrophic and interrelated complications of diabetes. Clin J Am Soc Nephrol 2006; 1: 193-208
23. Cohn JN. New therapeutic strategies for heart failure: left ventricular remodeling as a target. J Card Fail 2004; 10 (6 Suppl.): S200-1
24. Pieske B, Wachter R. Impact of diabetes and hypertension on the heart. Curr Opin Cardiol 2008; 23: 340-9
25. Ingelsson E, Sundstrom J, Arnlov J, et al. Insulin resistance and risk of congestive heart failure. JAMA 2005; 294: 334-41
26. Wright Jr JT, Harris-Haywood S, Pressel S, et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: anti-hypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Arch Intern Med 2008; 168: 207-17
27. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-9
28. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-62
29. Cushman WC, Grimm Jr RH, Cutler JA, et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007; 99 (12A): 44i-55i
30. Franco V, Oparil S. Salt sensitivity, a determinant of blood pressure, cardiovascular disease and survival. J Am Coll Nutr 2006; 25 (3 Suppl.): 247S-55S
31. Strojek K, Nicod J, Ferrari P, et al. Salt-sensitive blood pressure: an intermediate phenotype predisposing to diabetic nephropathy? Nephrol Dial Transplant 2005; 20: 2113-9
32. Dodson PM, Beevers M, Hallworth R, et al. Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. Brit Med J 1989; 298: 227-30
33. Sturrock ND, George E, Pound N, et al. Non-dipping circadian blood pressure and renal impairment are associated with increased mortality in diabetes mellitus. Diabet Med 2000; 17: 360-4
34. Czupryniak L, Paw"owski M, Saryusz-Wolska M, et al. Circadian blood pressure variation and antihypertensive medication adjustment in normo-albuminuric type 2 diabetes patients. Kidney Blood Press Res 2007; 30: 182-6
35. Minutolo R, Gabbai FB, Borrelli S, et al. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial. Am J Kidney Dis 2007; 50: 908-17
36. Medow MS, Stewart JM, Sanyal S, et al. Pathophysiology, diagnosis, and treatment of orthostatic hypotension and vasovagal syncope. Cardiol Rev 2008; 16: 4-20
37. Chobanian AV, Bakris GL, Black HR, et al., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560-72
38. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008; 31 Suppl. 1: S12-54
39. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410-9
40. Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-35
41. Lindholm LH, Hansson L, Ekbom T, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 2000; 18: 1671-5
42. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: interventionasaGoal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-72
43. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-65
44. Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. Arch Intern Med 2005; 165 (12): 1401-9
45. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006; 47: 352-8
46. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002; 62: 243-62
47. Sica DA. Thiazide-type diuretics and their use in hypertension: con position. J Clin Hypertens 2005; 7: 117-20
48. Alderman MH. New onset diabetes during antihypertensive therapy. Am J Hypertens 2008; 21: 493-9
49. Jonas M, Reicher-Reiss H, Boyko V, et al. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group. Am J Cardiol 1996; 77: 1273-7
50. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-20
51. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. LIFE Study Group. Lancet 2002; 359: 1004-10
52. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. ASCOT Investigators. Lancet 2005; 366: 895-906
53. Ostergren J, Poulter NR, Sever PS, et al. The anglo-scandinavian cardiac outcomes trial: blood pressure-lowering limb: effects in patients with type II diabetes. ASCOT investigators. J Hypertens 2008; 26 (11): 2103-11
54. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364: 1684-9
55. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-53
56. Goldstein S. β-Blockers in hypertensive and coronary heart disease. Arch Intern Med 1996; 156: 1267-76
57. Fonarow GC. Practical considerations of beta-blockade in the management of the post-myocardial infarction patient. Am Heart J 2005; 149: 984-3
58. Bangalore S, Parkar S, Grossman E, et al. A meta-analysis of 94 492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007; 100: 1254-62
59. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. GEMINI Investigators. JAMA 2004; 292: 2227-36
60. Sica DA. Pharmacotherapy review: calcium channel blockers. J Clin Hypertens (Greenwich) 2006; 8: 53-6
61. Bakris GL. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich) 2008; 10 (1 Suppl. 1): 27-32
62. Jamerson KA, Weber MA, Bakris GL. Avoiding cardiovascular events through combination therapy in patients living with systolic hypertension: the early termination of the ACCOMPLISH trial for efficacy. Session 407, ACC 57th Annual Scientific Session; 2008 Mar 29-Apr 1; Chicago (IL)
63. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. Collaborative Study Group. N Engl J Med 2001; 345: 851-60
64. Bakris GL, Weir MR, DeQuattro V,etal. Effects ofan ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54: 1283-9
65. Segura J, Garcia-Donaire JA, Ruilope LM. Are differences in calcium antagonists relevant across all stages of nephropathy or only proteinuric nephropathy? Curr Opin Nephrol Hypertens 2007; 16: 422-6
66. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Int Med 2003; 138: 593-602
67. Sica DA. Pharmacotherapy review: angiotensin-converting enzyme inhibitors. J Clin Hypertens (Greenwich) 2005; 7: 485-8
68. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450-6
69. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of ACE inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41: 1529-38
70. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic review of individual data from 100 000 patients in randomized trials. Circulation 1998; 97: 2202-12
71. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53
72. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). EUROpean trial on reduction of cardiac events with Perindopril in stable coronary Artery disease investigators. Lancet 2003; 362: 782-8
73. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-62
74. Lebovitz HE, Wiegmann TB, Cnaan A, et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994; 45: S150-5
75. Viberti G, Mogensen CE, Groop LC, et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994; 271: 275-9
76. Strippoli GF, Craig M, Deeks JJ, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004; 329: 828-39
77. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting enzyme inhibition in type 2 diabetes and nephropathy. Diabetics Exposed to Telmisartan and Enalapril Study Group. N Engl J Med 2004; 351: 1952-61
78. Marre M, Lievre M, Chatellier G, et al. Effects of low dose ramipril on cardiovascular and renal outcomesinpatients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). DIABHYCAR Study Investigators. BMJ 2004; 328: 495
79. Mann JF, Gerstein HC, Yi QL, et al. Development of renal disease in people at high cardiovascular risk: results ofthe HOPE randomized study.JAmSoc Nephrol 2003; 14: 641-7
80. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmi-sartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. ONTAR-GET investigators. Lancet 2008 Aug 16; 372 (9638): 547-53
81. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28-31
82. UKPDS 69. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus. Arch Ophthalmol 2004; 122: 1631-40
83. Douketis JD, Sharma AM. The management of hypertension in the overweight and obese patient: is weight reduction sufficient? Drugs 2004; 64: 795-803
84. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. Second Australian National Blood Pressure Study Group. N Engl J Med 2002; 348: 583-92
85. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 1981-97
86. Barzilay JI, Davis BR, Cutler JA, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Collaborative Research Group. Arch Intern Med 2006; 166 (20): 2191-201
87. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. HOPE Study Investigators. JAMA 2001; 286: 1882-5
88. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Capto-pril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6
89. Lindholm LH, Ibsen H, Borch-Johnsen K, et al., for the LIFE study group. Risk of new-onset diabetes in the Losartan Intervention for Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879-86
90. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlo-dipine: the VALUE randomised trial. VALUE trial group. Lancet 2004; 363: 2022-31
91. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM overall programme. CHARM Investigators and Committees. Lancet 2003; 362: 759-68
92. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369 (9557): 201-7
93. Jandeleit-Dahm KA, Tikellis C, Reid CM, et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23: 463-73
94. Sica DA. Pharmacotherapy review: angiotensin receptor antagonists. J Clin Hypertens (Greenwich) 2005; 7: 681-4
95. Kjeldsen SE, Julius S, Mancia G, et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. VALUE Trial Investigators. J Hypertens 2006; 24: 1405-12
96. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. N Engl J Med 2001; 345: 870-8
97. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. RENAAL Study Investigators. N Engl J Med 2001; 345: 861-9
98. Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Irbesartan Diabetic Nephropathy Trial Collaborative Study Group. Ann Intern Med 2003; 138: 542-9
99. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. ONTARGET Investigators. N Engl J Med 2008; 358: 1547-59
100. Reboldi G, Angeli F, Cavallini C, et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens 2008; 26 (7):1282-9
101. Verberk WJ, Kroon AA, Kessels AG, et al. Home blood pressure measurement: a systematic review. J Am Coll Cardiol 2005; 46: 743-51
102. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1. Blood pressure measurement in humans - a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005; 111: 697-716
103. Verberk WJ, Kroon AA, Kessels AG, et al. Self-measurement of blood pressure at home reduces the need for antihypertensive drugs: a randomized, controlled trial. Home versus office measurement, reduction of unnecessary treatment study investigators. Hypertension 2007; 50: 1019-25
104. Turnbull F, Neal B, Pfeffer M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. Blood Pressure Lowering Treatment Trialists' Collaboration.J Hypertens 2007; 25: 951-8
105. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366: 2026-33
106. Sica DA. Combination ACE inhibitor and angiotensin receptor blocker therapy: future considerations. J Clin Hypertens (Greenwich) 2007; 9: 78-86
107. Patel A, McMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. ADVANCE Collaborative Group. Lancet 2007; 370: 829-40
108. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. ADVANCE Collaborative Group. N Engl J Med 2008; 358 (24): 2560-72